Free Trial
NYSE:RMD

ResMed (RMD) Stock Price, News & Analysis

$237.90
-12.98 (-5.17%)
(As of 09/18/2024 ET)

About ResMed Stock (NYSE:RMD)

Key Stats

Today's Range
$231.48
$242.03
50-Day Range
$197.04
$252.92
52-Week Range
$132.24
$255.18
Volume
1.89 million shs
Average Volume
1.05 million shs
Market Capitalization
$34.95 billion
P/E Ratio
36.54
Dividend Yield
0.89%
Price Target
$199.70
Consensus Rating
Hold

Company Overview

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.

ResMed Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks

Overall MarketRank™: 95th Percentile

ResMed scored higher than 95% of companies evaluated by MarketBeat, and ranked 67th out of 1,014 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ResMed has received a consensus rating of Hold. The company's average rating score is 2.30, and is based on 4 buy ratings, 5 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    ResMed has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about ResMed's stock forecast and price target.
  • Earnings Growth

    Earnings for ResMed are expected to grow by 8.30% in the coming year, from $8.92 to $9.66 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ResMed is 36.54, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 135.39.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ResMed is 36.54, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 140.32.

  • Price to Earnings Growth Ratio

    ResMed has a PEG Ratio of 2.49. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    ResMed has a P/B Ratio of 7.19. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about ResMed's valuation and earnings.
  • Percentage of Shares Shorted

    5.82% of the outstanding shares of ResMed have been sold short.
  • Short Interest Ratio / Days to Cover

    ResMed has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in ResMed has recently decreased by 12.58%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ResMed has a dividend yield of 0.85%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    ResMed has been increasing its dividend for 13 years.

  • Dividend Coverage

    The dividend payout ratio of ResMed is 32.57%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, ResMed will have a dividend payout ratio of 21.95% next year. This indicates that ResMed will be able to sustain or increase its dividend.

  • Read more about ResMed's dividend.
  • Percentage of Shares Shorted

    5.82% of the outstanding shares of ResMed have been sold short.
  • Short Interest Ratio / Days to Cover

    ResMed has a short interest ratio ("days to cover") of 7.9.
  • Change versus previous month

    Short interest in ResMed has recently decreased by 12.58%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    ResMed has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 21 news articles for ResMed this week, compared to 8 articles on an average week.
  • Search Interest

    Only 7 people have searched for RMD on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added ResMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -71% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, ResMed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,644,807.00 in company stock.

  • Percentage Held by Insiders

    Only 1.21% of the stock of ResMed is held by insiders.

  • Percentage Held by Institutions

    54.98% of the stock of ResMed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about ResMed's insider trading history.

RMD Stock News Headlines

ResMed Inc. (NYSE:RMD) Insider Sells $1,262,800.00 in Stock
War on Elon Escalates…
Elon Musk, the guy slated to become the world’s first trillionaire by 2027, has publicly called for the adoption of this technology for decades. By doing so he has put himself in the crosshairs of an ideological war with the global elites. And yet, while this new technology threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
ResMed Inc. (NYSE:RMD) Director Sells $479,800.00 in Stock
Why ResMed Stock Tumbled by 5% Today
SPY ETF Update, 9/17/2024
See More Headlines

RMD Stock Analysis - Frequently Asked Questions

ResMed's stock was trading at $172.02 at the beginning of the year. Since then, RMD stock has increased by 38.3% and is now trading at $237.90.
View the best growth stocks for 2024 here
.

ResMed Inc. (NYSE:RMD) announced its quarterly earnings results on Thursday, August, 1st. The medical equipment provider reported $2.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.03 by $0.05. The firm's quarterly revenue was up 6.9% on a year-over-year basis.
Read the conference call transcript
.

The following companies are subsidiaries of ResMed: Propeller Health, and Matrixcare.

Top institutional investors of ResMed include Bank of New York Mellon Corp (3.93%), Los Angeles Capital Management LLC (0.50%), Greenvale Capital LLP (0.49%) and Dimensional Fund Advisors LP (0.45%). Insiders that own company stock include Michael J Farrell, Robert Andrew Douglas, Brett Sandercock, David Pendarvis, Peter C Farrell, Kaushik Ghoshal, Justin Leong, Michael J Rider, Karen Drexler, Witte Jan De, Lucile Blaise, Carol Burt and James Hollingshead.
View institutional ownership trends
.

Shares of RMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that ResMed investors own include NVIDIA (NVDA), Walt Disney (DIS), Intel (INTC), AbbVie (ABBV), Netflix (NFLX), Adobe (ADBE) and Visa (V).

Company Calendar

Last Earnings
8/01/2024
Ex-Dividend for 9/19 Dividend
8/15/2024
Today
9/18/2024
Dividend Payable
9/19/2024
Next Earnings (Estimated)
10/24/2024
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
CUSIP
76115210
Employees
9,980
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$199.70
High Stock Price Target
$251.00
Low Stock Price Target
$165.00
Potential Upside/Downside
-16.1%
Consensus Rating
Hold
Rating Score (0-4)
2.30
Research Coverage
10 Analysts

Profitability

Net Income
$1.02 billion
Pretax Margin
27.00%

Debt

Sales & Book Value

Annual Sales
$4.69 billion
Cash Flow
$8.76 per share
Book Value
$33.11 per share

Miscellaneous

Free Float
145,129,000
Market Cap
$34.95 billion
Optionable
Optionable
Beta
0.69

Social Links

Should I Buy ResMed Stock? RMD Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, September 3, 2024. Please send any questions or comments about these ResMed pros and cons to contact@marketbeat.com.

ResMed
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ResMed Inc.:

  • ResMed Inc. reported strong earnings results, beating analysts' consensus estimates, indicating a healthy financial performance.
  • The company has a solid revenue growth rate, with a 6.9% increase compared to the same quarter last year, showcasing positive business momentum.
  • ResMed Inc. has a high return on equity of 25.00%, reflecting efficient utilization of shareholder funds to generate profits.
  • Recent insider transactions show confidence in the company, with insiders owning a notable percentage of the company's stock.
  • ResMed Inc.'s stock price has been trading up, indicating positive market sentiment and potential for capital appreciation.

ResMed
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ResMed Inc. for these reasons:

  • The company's price-to-earnings ratio of 37.35 is relatively high, suggesting the stock may be overvalued compared to industry peers.
  • ResMed Inc. has a debt-to-equity ratio of 0.14, which may indicate a higher level of financial leverage and associated risks.
  • While the company has shown revenue growth, the price-to-earnings-growth ratio of 2.31 may imply a premium valuation relative to its growth prospects.
  • Institutional investors own a significant portion of the company's stock (54.98%), potentially leading to less influence for individual retail investors.
  • CEO and general counsel selling significant amounts of company stock may raise concerns about insider sentiment and future performance expectations.

This page (NYSE:RMD) was last updated on 9/18/2024 by MarketBeat.com Staff
From Our Partners